Feb 27 (Reuters) - Brainchip Holdings Ltd BRN.AX:
BRAINCHIP EVALUATES REDOMICILING TO US
BRAINCHIP EVALUATES REDOMICILING TO US IN 2025
DECISION TO INVESTIGATE REDOMICILING WAS REACHED AFTER BOARD CONDUCTED AN EXTENSIVE STRATEGIC REVIEW OF COMPANY
BOARD DETERMINED THAT A SOLE US LISTING WAS IN BEST INTERESTS OF BRAINCHIP SHAREHOLDERS
WOULD SEEK TO SIMULTANEOUSLY DELIST SECURITIES FROM QUOTATION ON AUSTRALIAN SECURITIES EXCHANGE
Further company coverage: BRN.AX
((Reuters.Briefs@thomsonreuters.com;;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.